Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 3 2Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Screening 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 81Carboplatin 76Magnetic Resonance Spectroscopy 73Specimen Handling 69Cisplatin 62Paclitaxel 55Gemcitabine 46Fluorouracil 37Dexamethasone 37Radiation 36Docetaxel 36Cyclophosphamide 36Radiotherapy 35Pemetrexed 35Doxorubicin 35Oxaliplatin 33Leucovorin 33Bevacizumab 31Capecitabine 28Vincristine 27durvalumab 26Etoposide 24Rituximab 23Taxes 22Irinotecan 22Nivolumab 21Letrozole 21Prednisone 20Biopsy 20Platinum 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Genetic Testing × 30 days × Clear all
NCT06058377 2026-05-27

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT03233191 2026-05-05

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
108,508 enrolled
Breast

Breast Screening

Data powered by HemOnc (CC BY 4.0) Colophon âš¡